Rock Springs Capital Management LP Sarepta Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

$1.67 Billion
Q1 2025

A detailed history of Rock Springs Capital Management LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 159,300 shares of SRPT stock, worth $5.62 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

159,300

Previous 307,500 48.2%

Holding current value

$5.62 Million

Previous $37.4 Million 72.81%

% of portfolio

0.61%

Previous 1.49%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$63.82 - $127.89 $9.46 Million - $19 Million	-148,200 Reduced 48.2%	159,300 $10.2 Million
Q3 2024 Nov 14, 2024	BUY	$124.33 - $156.75 $2.92 Million - $3.68 Million	23,500 Added 8.27%	307,500 $38.4 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $4.94 Million - $7.14 Million	-43,600 Reduced 13.31%	284,000 $44.9 Million
Q4 2023 Feb 14, 2024	SELL	$67.31 - $124.76 $4.33 Million - $8.03 Million	-64,400 Reduced 16.43%	327,600 $31.6 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $3.38 Million - $4.08 Million	-33,000 Reduced 7.76%	392,000 $47.5 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $1.86 Million - $2.75 Million	-17,500 Reduced 3.95%	425,000 $48.7 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $763,945 - $1.01 Million	6,500 Added 1.49%	442,500 $61 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $605,160 - $792,780	6,000 Added 1.4%	436,000 $56.5 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $151,420 - $238,480	2,000 Added 0.47%	430,000 $47.5 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $252,600 - $361,680	4,000 Added 0.94%	428,000 $33.4 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $5.72 Million - $7.36 Million	74,000 Added 21.14%	424,000 $38.2 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $1.4 Million - $1.97 Million	21,250 Added 6.46%	350,000 $32.4 Million
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $2.1 Million - $2.99 Million	-16,750 Reduced 4.85%	328,750 $56 Million
Q4 2019 Feb 14, 2020	BUY	$76.53 - $135.58 $612,240 - $1.08 Million	8,000 Added 2.37%	345,500 $44.6 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $910,125 - $1.96 Million	12,500 Added 3.85%	337,500 $25.4 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $1.07 Million - $1.44 Million	-9,500 Reduced 2.84%	325,000 $49.4 Million
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $800,025 - $1.14 Million	7,500 Added 2.29%	334,500 $39.9 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $1.61 Million - $2.45 Million	16,500 Added 5.31%	327,000 $35.7 Million
Q3 2018 Nov 14, 2018	BUY	$115.31 - $161.51 $1.5 Million - $2.1 Million	13,000 Added 4.37%	310,500 $50.1 Million
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $2.83 Million - $6.07 Million	39,500 Added 15.31%	297,500 $39.3 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $57,168 - $68,100	-1,200 Reduced 0.46%	258,000 $14.4 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $9.26 Million - $12.2 Million	259,200	259,200 $11.8 Million

Others Institutions Holding SRPT

# of Institutions

507

Shares Held

88.7M

Call Options Held

1.39M

Put Options Held

1.13M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $3.09B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Sarepta Therapeutics, Inc. Transaction History